A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2019
At a glance
- Drugs Ipilimumab (Primary) ; Interferon alpha-2b; Interferon alpha-2b
- Indications Malignant melanoma
- Focus Therapeutic Use
- 20 Dec 2018 Planned End Date changed from 1 Dec 2014 to 1 Oct 2025.
- 31 Aug 2018 Biomarkers information updated
- 28 Nov 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2017.